Nunes Filho Paulo, Albuquerque Caroline, Pilon Capella Mariana, Debiasi Marcio
Labcorp Drug Development, Burlington, NC, USA.
Rua Augusto Pestana, 25/92, Porto Alegre, RS, Brazil.
Oncol Ther. 2023 Jun;11(2):171-183. doi: 10.1007/s40487-023-00224-9. Epub 2023 Mar 14.
Breast cancer is the most frequently diagnosed malignancy in patients worldwide and the main cause of cancer-related death. Though still incurable, metastatic breast cancer's prognosis has been considerably improved in the past 10 years due to the introduction of new targeted agents, such as immune checkpoint inhibitors (ICI). However, these medications are associated with unique side effects known as immune-mediated adverse events (irAE). In this paper, we review the clinical evidence for the use of ICIs in breast cancer, in both the metastatic as well as neoadjuvant/adjuvant setting, followed by a review of irAE most commonly seen, and the medications used to treat them. Our opinion is that any cancer specialist treating patients with breast cancer should be aware of these side effects for early detection and management, and oncologists should be the leaders of the multidisciplinary team that will take care of them.
乳腺癌是全球患者中最常被诊断出的恶性肿瘤，也是癌症相关死亡的主要原因。尽管转移性乳腺癌仍无法治愈，但在过去10年中，由于引入了新的靶向药物，如免疫检查点抑制剂（ICI），其预后已得到显著改善。然而，这些药物会引发独特的副作用，即免疫介导的不良事件（irAE）。在本文中，我们回顾了ICI在转移性以及新辅助/辅助治疗环境下用于乳腺癌治疗的临床证据，随后回顾了最常见的irAE以及用于治疗它们的药物。我们认为，任何治疗乳腺癌患者的癌症专科医生都应了解这些副作用以便早期发现和处理，肿瘤学家应成为负责处理这些副作用的多学科团队的领导者。
